Digest Network Come funziona
Network
/
Società
Or
Non verificato

Orum Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

10 comunicati stampa

Guarda tutti i comunicati
17/04/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Orum Therapeutics Presents New Preclinical Data at AACR 2026 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in Acute Myeloid Leukemia and the Potential for Improved Efficacy and Tolerability
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
13/04/2026
Mercato del lavoro
Biologia
Biotecnologia
Salute
Sanità
Farmaceutica
Oncologia
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
17/03/2026
Scienza
Medicina - Varie
Biologia
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
Industria
Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
04/01/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Mercato del lavoro
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
18/12/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Industria
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
03/11/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
15/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Mercato del lavoro
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
02/10/2024
Titoli e azioni
Oncologia
Salute
Sanità
Farmaceutica
Biotecnologia
Orum Therapeutics Submits Registration Statement for KOSDAQ Listing
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0
16/07/2024
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum’s TPD²® Technology to Develop Novel Degrader-Antibody Conjugates
Fonte
Orum Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0